Cellenion will provide a full range of single cell analysis and manipulation services from its new state-of-the-art laboratories in
Cellenion, a BICO company, today announced the opening of the first
Cellenion has developed cellenONE®, a unique single cell isolation and nanoliter dispensing technology enabling image-based high-throughput dispensing of single cells from cell suspensions and precision dispensing of reagents to automate and miniaturize sample preparation prior to single cell analyses. By opening this service, Cellenion will bring its unique technology platform and strong expertise in the field of single cell isolation and sample preparation to a much wider audience.
Initially focusing on single-cell transcriptomic analyzes using cellenONE, Cellenion plans to diversify its offering into other areas of expertise such as automated cloning for cell line development and aggregate sorting and isolation. 3D cells (spheroids and organoids) using its recently launched product, spheroONE.
For more information on Cellenion’s services, visit: www.cellenion.com/services
For more information, please contact:
Phone (US): +1 (617) 637 5372
Email: [email protected]
This information was submitted for publication, through the contact persons indicated above, on March 3, 2022 at 2:00 p.m. (CET).
Cellenion offers solutions and technologies for controlled cell killing with applications in the areas of single cell isolation and single cell aggregates. Our systems enable automated, high-throughput, image-based delivery of single cells and/or cell aggregates onto any substrates of your choice. Associated with a range of dedicated consumables, the solutions allow the miniaturization of sample preparation protocols on the same instrument before downstream analysis. With no dead volume and exceptional recovery rates, Cellenion’s platforms offer unique capabilities for applications such as single cell omics, rare cells, cell line development, drug screening and 3D model development. Cellenion has been operating since
Founded in 2016, BICO (formerly
Focusing on the application areas of bioprinting, multiomics, cell line development and diagnostics, the company develops and commercializes innovative technologies that enable life science researchers to grow cells in 3D, to perform high-throughput drug screening and to print human tissues and organs for the medical, pharmaceutical and cosmetic industries. We are creating the future of healthcare.
The Group’s products are trusted by more than 25,000 laboratories, including the 20 largest pharmaceutical companies, are used in more than 65 countries and have been cited in more than 9,500 publications. BICO is listed on Nasdaq Stockholm under BICO. www.bico.com
(c) Decision 2022. All rights reserved., sources